§328-15 - Drugs or devices deemed misbranded when; prescriptions excepted, when.

§328-15 Drugs or devices deemed misbranded
when; prescriptions excepted, when. A drug or device shall be deemed to be
misbranded:

(1) If its labeling is false or misleading in any
particular, or if its labeling or packaging fails to conform with the requirements
of section 328-19.1.

(2) If in package form, unless it bears a label
containing:

(A) The name and place of business of the
manufacturer, packer, or distributor; and

(B) An accurate statement of the quantity of
the contents in terms of weight, measure, or numerical count, which statement
shall be separately and accurately stated in a uniform location upon the
principal display panel of the label, provided that under this subparagraph
reasonable variations shall be permitted, and exemptions as to small packages
shall be allowed, in accordance with rules adopted by the director. An
accurate statement of the quantity of the contents in terms of weight, measure,
or numerical count shall not be required for any commodity subject to packaging
and labeling requirements imposed by the Secretary of Agriculture pursuant to
the Federal Insecticide, Fungicide, and Rodenticide Act or the provisions of
the eighth paragraph under the heading "Bureau of Animal Industry" of
the Act of March 4, 1913 (37 Stat. 832-833; 21 U.S.C. §§151-158), commonly
known as the Virus-Serum-Toxin Act.

(3) If any word, statement, or other information
required by or under authority of this part to appear on the label or labeling
is not prominently placed thereon with such conspicuousness (as compared with
other words, statements, designs, or devices, in the labeling) and in such
terms as to render it likely to be read and understood by the ordinary
individual under customary conditions of purchase and use.

(4) If it is for use by a person and contains any
quantity of the narcotic or hypnotic substance alpha-eucaine, barbituric acid,
beta-eucaine, bromal, cannabis, cabromal, chloral, coca, cocaine, codeine,
heroin, marijuana, morphine, opium, paraldehyde, peyote, or sulphomethane, or
any chemical derivative of such substance, which derivative, after
investigation, has been found to be and designated as habit forming, by rules
adopted by the director under this part, or by regulations issued pursuant to
section 502(d) of the Federal Act, unless its label bears the name and quantity
or proportion of the substance or derivative and in juxtaposition therewith the
statement "Warning--May be habit forming."

(5) (A) If it is a drug unless:

(i) Its label bears, to the exclusion of any
other nonproprietary name (except the applicable systematic chemical name or
the chemical formula), the established name, as defined in subparagraph (B), of
the drug, if such there be; and in case it is fabricated from two or more
ingredients, the established name and quantity of each active ingredient,
including the kind and quantity or proportion of any alcohol, and also
including, whether active or not, the established name and quantity or
proportion of any bromides, ether, chloroform, acetanilid, acetophenetidin,
amidopyrine, antipyrine, atropine, hyoscine, hyoscyamine, arsenic, digitalis,
glucosides, mercury, ouabain, strophanthin, strychnine, thyroid, or any
derivative or preparation of any such substances, contained therein; provided
that the requirement for stating the quantity of the active ingredients, other
than the quantity of these specifically named in this paragraph, shall apply
only to prescription drugs; and

(ii) For any prescription drug the established
name of such drug or ingredient, as the case may be, on such label (and on any
labeling on which a name for such drug or ingredient is used) is printed
prominently and in type at least half as large as that used thereon for any
proprietary name or designation for such drug or ingredient; provided further
that to the extent that compliance with the requirements of this subparagraph
is impracticable, exemptions shall be allowed under rules adopted by the
director.

(B) As used in this paragraph, the term
"established name", with respect to a drug or ingredient thereof,
means:

(i) The applicable official name designated
pursuant to section 508 of the Federal Act;

(ii) If there is no such name and the drug, or
the ingredient, is an article recognized in an official compendium, then the
official title thereof in the compendium; or

(iii) If neither clause (i) nor clause (ii) of
this subparagraph applies, then the common or usual name, if any, of such drug
or of the ingredient;

provided further that where clause (ii) of this
subparagraph applies to an article recognized in the United States
Pharmacopoeia, in the United States Pharmacopoeia Dispensing Information, and
in the Homeopathic Pharmacopoeia under different official titles, the official
title used in the United States Pharmacopoeia shall apply unless it is labeled
and offered for sale as a homeopathic drug, in which case the official title
used in the Homeopathic Pharmacopoeia shall apply.

(6) Unless its labeling bears:

(A) Adequate directions for use; and

(B) Such adequate warnings against use in
those pathological conditions or by children where its use may be dangerous to
health, or against unsafe dosage or methods or duration of administration or
application, in such manner and form, as are necessary for the protection of
users; provided that where any requirement of subparagraph (A), as applied to
any drug or device, is not necessary for the protection of the public health,
the director shall adopt rules exempting the drug or device from such
requirements; provided further that articles exempted under regulations issued
under section 502(f) of the Federal Act may also be exempt.

(7) If it purports to be a drug the name of which is
recognized in an official compendium, unless it is packaged and labeled as
prescribed therein; provided that the method of packaging may be modified with
the consent of the director, or if consent is obtained under the Federal Act.
Whenever a drug is recognized in both the United States Pharmacopoeia and the
Homeopathic Pharmacopoeia of the United States, it shall be subject to the
requirements of the United States Pharmacopoeia with respect to the packaging
and labeling unless it is labeled and offered for sale as a homeopathic drug,
in which case it shall be subject to the Homeopathic Pharmacopoeia of the
United States and not to the United States Pharmacopoeia; provided that in the
event of inconsistency between the requirements of this paragraph and those of
paragraph (5) as to the name by which the drug or its ingredients shall be
designated, the requirements of paragraph (5) shall prevail.

(8) If it has been found by the director to be a drug
liable to deterioration, unless it is packaged in such form and manner, and its
label bears a statement of such precautions, as the rules adopted by the director
or regulations issued under the Federal Act require as necessary for the
protection of public health. No such rule shall be established for any drug
recognized in an official compendium until the director shall have informed the
appropriate body charged with the revision of the compendium of the need for
such packaging or labeling requirements and such body shall have failed within
a reasonable time to prescribe such requirements.

(9) (A) If it is a drug and its container is so
made, formed, or filled as to be misleading;

(B) If it is an imitation of another drug; or

(10) If it is dangerous to health when used in the
dosage, or with the frequency or duration prescribed, recommended, or suggested
in the labeling thereof.

(11) If it is, purports to be, or is represented as a
drug composed wholly or partly of insulin, unless:

(A) It is from a batch with respect to which a
certificate or release has been issued pursuant to section 506 of the Federal
Act; and

(B) The certificate or release is in effect
with respect to the drug.

(12) If it is, purports to be, or is represented as a
drug composed wholly or partly of any kind of penicillin, streptomycin,
chlortetracycline, chloramphenicol, bacitracin, or any other antibiotic drug,
or any derivative thereof, unless:

(A) It is from a batch with respect to which a
certificate or release has been issued pursuant to section 507 of the Federal
Act; and

(B) The certificate or release is in effect
with respect to the drug; provided that this paragraph shall not apply to any
drug or class of drugs exempted by regulations promulgated under section 507(c)
or (d) of the Federal Act.

For the purpose of this paragraph, the term
"antibiotic drug" means any drug intended for use by a person
containing any quantity of any chemical substance which is produced by a
microorganism and which has the capacity to inhibit or destroy microorganisms
in dilute solution (including the chemically synthesized equivalent of any such
substance).

(13) If it is a color additive, the intended use of
which in or on drugs is for the purpose of coloring only, unless its packaging
and labeling are in conformity with the packaging and labeling requirements
applicable to such color additive prescribed under section 328-13(b).

(14) In the case of any prescription drug distributed
or offered for sale in this State, unless the manufacturer, packer, or
distributor thereof includes in all advertisements and other descriptive
printed matter issued or caused to be issued by the manufacturer, packer, or
distributor with respect to that drug a true statement of:

(A) The established name, as defined in
paragraph (5)(B), printed prominently and in type at least half as large as
that used for any trade or brand name thereof;

(B) The formula showing quantitatively each
ingredient of the drug to the extent required for labels under section 502(e)
of the Federal Act; and

(C) Such other information in brief summary
relating to side effects, contra-indications, and effectiveness as shall be
required in rules adopted by the director.

(15) If a trademark, trade name, or other identifying
mark, imprint, or device of another or any likeness of the foregoing has been
placed thereon or upon its container with intent to defraud.

(16) Drugs and devices which are, in accordance with
the practice of the trade, to be processed, labeled, or repacked in substantial
quantities at establishments other than those where originally processed or
packed shall be exempt from any labeling or packaging requirements of this
part; provided that such drugs and devices are being delivered, manufactured,
processed, labeled, repacked, or otherwise held in compliance with rules
adopted by the director.

(17) If it has met or exceeded the expiration date
established by the manufacturer or principal labeler. [L 1941, c 318, §11; RL
1945, §2215; RL 1955, §51-15; am L Sp 1959 2d, c 1, §19; am L 1963, c 36, §1;
am L 1964, c 15, §§2, 3; am L 1967, c 152, §9; HRS §328-15; am L 1972, c 151,
§8; gen ch 1993; am L 1997, c 214, §3]